
Summing Up the Second Day: OSIRIS Third Workshop, 2 March 2010

Mark Cronin School of Pharmacy and Chemistry Liverpool John Moores University England



BfR Decision Support System

- A tool for predicting local effects i.e. skin irritation and corrosion
- Based on confidential business information
- Strong mechanistic basis, assists in regulatory acceptance
- Predicts non-irritants as well as irritants
- Includes cut-offs and structural alerts for toxicity
- Implemented in Toxtree / OECD (Q)SAR Application Toolbox

Skin Sensitisation: In Vitro

- No validated *in vitro* tests are available
- In vitro assays for skin sensitisation should be mechanistically based
 - Immune cell migration
 - Allergen presentation in lymph node
 - Proinflammatory cytokine / chemokine release
 - T cell differentiation
 - Tissue damage
- Colipa and Sens-it-iv projects cover the whole range of mechanisms
 - In silico, peptide reactivity, metabolic capacity, microarray analysis of dendritic cells, signal transduction in DC maturation etc
- DC-TC interaction (BfR CAATC assay) dendritic cell-induced expression of lineage specific T-cell transcription factors
- Timeframe for (accelerated) acceptance 6 years ?
- ECVAM: peptide reactivity; hCLAT; MUSST

Skin Sensitisation: In Silico

- Various in silico approaches exist
- Five approaches are used in the web-tool
- The approaches overlap but differ in terms of
 - Number and type of data
 - Mechanistic vs non-mechanistic approaches
 - Modelling philosophy
- Other approaches are available to predict skin sensitisation
- A method to integrate the predictions is required and is provided by the web-tool

Skin Sensitisation: Integrating Results with Bayesian Approaches

- Need to move to a simulation intense, data intense, explicit representation of mechanisms
- Bayesian Networks allow for causal effects etc to be retained.
- Hypotheses are developed and tested
 - Identify key parameters (i.e. Mechanistic tests)
 - Develop non-animal test methods
 - Integrate data from different test methods

Skin Sensitisation: Integrating Results with Bayesian Approaches

- Aim to Predict LLNA: non, weak, moderate, strong
- In silico: TIMES
- Battery of bioavailability indicators: log P, Potts and Gut, Kasting skin permeability
- In chemico: peptide reactivity: Lys, Cys, Luc
- In vitro: DC cells: IL-8, CD86
- 142 LLNA data many missing values for "alternatives" especially, Dendritic Cells
- Bayesian network illustrates which variables are important for activity (reactivity NS, M, S; bioavailability for W)

Bayesian WoE for REACH ITS Generation

- WoE needs: defined endpoints vs alternatives
- Defined endpoint is a REACH endpoint and acts as the gold standard; determine threshold probability using a gold standard / intra-test variability / expert judgement
- Need quality factors (e.g. Klimisch-like codes) for alternatives – method performance compared to REACH endpoint / gold standard
- Posterior Probability is compared to threshold.
- Optimisation function for the test proposal
- Various implementations: Excel, Hugin, Web-tool

World Cafe: Proof of Concept

- Sensitisation may be a categorical endpoint, but also partly continuous
- Proof of Concept: if endpoint is both categorical / continuous use both
- There is no perfect system, take note of limitations e.g. Impurities and formulations.
- Build a system for pure substances (deal with impurities / formulations separately)
- This approach is not possible for reproductive toxicity (development and fertility) as it is too complex – note relevance of ReProTect and ChemScreen EU FP projects

World Cafe: Proof of Concept

- Whilst alternatives for Repro Tox exist, for C&L OECD test is required. However for REACH, other tests are required.
- Regulatory acceptance is required to indicate whether proof of concept is valid – what is probability / certainty threshold required by regulators.

World Cafe: Can Reduced *in Vivo* Tests be Applied?

- More reduced versions are desirable:
 - Necessary to define an applicability domain for reduced test
 - Analyse existing in vivo data for sensitivity
- Ideas: reduced method for dermal toxicity and tests for multiple endpoints
- Move towards "realistic" test concentrations based on exposure concentrations
- Intelligent use of OECD guidelines to implement alternatives – ITS
- Use models to help getting to reduced tests

World Cafe: Can Reduced *in Vivo* Tests be Applied?

- Could perform mechanistic studies to direct reduced *in vivo* tests
- Flexibility is required in being able to choose a suitable test LLNA may still be required
- Data requirements will also dictate whether a reduced test can be used
- Reducing can also enhance testing via mechanistic hypothesis

World Cafe: Regulatory Approach to Uncertainty

- To require same level of probability is overrestricted
- +ve or -ve may have different levels of probability
- For continuous vs categorical probability should not be different (although QSAR treats them differently)
- Costs / animal welfare should be taken into account
- Gold standard should be choosen using Bayesian approach not only to include LLNA but also human and GPMT.

World Cafe: Regulatory Approach to Uncertainty

What is acceptable becomes a political issue

Acknowledgements

European Union 6th Framework OSIRIS Integrated Project (GOCE-037017-OSIRIS)

